Temasek Leads $50 Million Series B for PEAR Therapeutics
Posted on 01/03/2018
U.S.-based digital health firm PEAR Therapeutics has closed US$ 50 million in Series B financing led by Singapore’s Temasek Holdings. The funding round also received contributions from the corporate investment unit of the Singapore Economic Development Board, as well as a number of returning healthcare-centric investors, including 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, Novartis, […]
